MVT 2163

Drug Profile

MVT 2163

Alternative Names: 89Zr-DFO-HuMab-5B1; 89Zr-HuMab 5B1; MVT-2163; PET Imaging agent - MabVax Therapeutics; Radiolabelled 5B1 diabody (sLeA); Zirconium anti-sialyl Lewisa imaging agent - MabVax

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HonorHealth; MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Preclinical Bladder cancer; Colorectal cancer; Small cell lung cancer

Most Recent Events

  • 04 Oct 2017 Pharmacokinetics data from a preclinical study in Pancreatic cancer diagnosis released by MabVax
  • 22 Aug 2017 MabVax completes the phase I trial in Pancreatic cancer (Diagnosis, Late-stage disease, Metastatic disease) in USA, before August 2017
  • 14 Jun 2017 Pharmacokinetics and safety data from a phase I trial in Pancreatic cancer (Diagnosis) released by MabVax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top